Pfizer Reports China Trial Results for Lyrica
August 13, 2014 at 06:13 AM EDT
Pfizer reported mixed results from two China trials of Lyrica ® , an anti-seizure drug that is also effective against some forms of neuropathic and chronic pain. Lyrica successfully reduced pain in a Phase IV follow-up study of patients with postherpetic neuralgia (PHN), the pain that follows shingles. But Lyrica did not meet its endpoints in a Phase III trial among patients with painful diabetic peripheral neuropathy (pDPN). More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //